论文部分内容阅读
目的探讨TACE联合拉米夫定抗病毒治疗在肝癌治疗中的作用。方法将2009年12月—2010年12月我院接受TACE治疗的病人分为A组24例,B组TACE+拉米夫定抗病毒治疗24例,术前给拉米夫定100mg,1次/日口服。结果 A组治疗过程中出现肝炎活动50%(12/24),中度肝炎活动为20.8%(5/24),重度肝炎活动29%(7/24);B组发生肝炎活动25%(6/24),轻度肝炎8%(2/24),中度肝炎活动为16.7%(4/24);病毒再激活:A组45.8%(11/24),B组:无。1年生存率:A组62.5%(15/24),B组79.2%(19/24),两组相比差异有统计学意义(P<0.05)。结论肝动脉化疗栓塞术联合拉米夫定抗病毒治疗在肝癌治疗中起积极作用。
Objective To explore the role of TACE combined with lamivudine antiviral therapy in the treatment of liver cancer. Methods The patients who received TACE treatment in our hospital from December 2009 to December 2010 were divided into 24 cases in group A. In group B, 24 patients were treated with TACE+lamivudine antiviral therapy, and 100 mg of lamivudine was given before operation. Orally. Results In group A, 50% (12/24) of the activities of hepatitis occurred during treatment, 20.8% (5/24) of moderate hepatitis activity, 29% (7/24) of severe hepatitis activity, and 25% of hepatitis activity in group B (6). /24), Mild hepatitis 8% (2/24), moderate hepatitis activity 16.7% (4/24); virus reactivation: 45.8% (11/24) in group A, group B: none. One-year survival rate was 62.5% (15/24) in group A and 79.2% (19/24) in group B. There was a significant difference between the two groups (P<0.05). Conclusion Hepatic arterial chemoembolization combined with lamivudine antiviral therapy plays an active role in the treatment of hepatocellular carcinoma.